Treatment of non-small cell lung cancer with gefitinib

Zhonghua Jiehe he Huxi Zazhi

Volumn 28, Issue 3, 2005, Pages 180-183

  Zhang, Xiao Tong ^a   Li, Long Yun ^a   Wang, Shu Lan ^a   Mu, Xin Lin ^a   Wang, Meng Zhao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Carcinoma, non small cell lung; Gefitinib; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DIARRHEA; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; QUALITY OF LIFE; RASH; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 33751249049     PISSN: 10010939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19:1734-1742.
2. Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346:92-98.
3. Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47:207-214.
4. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9:129-137.
5. Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79:538-544.
6. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res, 2000, 6:747-753.
7. Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7:1459-1465.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21:2237-2246.
9. LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003, 9:2040-1048.
10. Kris M, Natale R, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290:2149-2158.